Donor-derived cell free DNA as a biomarker in kidney transplantation.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-09-01 Epub Date: 2023-09-21 DOI:10.2217/pgs-2023-0138

Tarek Abdulhadi, Louai Alrata, Casey Dubrawka, Gwendolyn Amurao, Sri Mahathi Kalipatnapu, Che Isaac, Shelden Rodrigues, Karen Marie Flores, Dema Yaseen Alsabbagh, Omar Alomar, Tarek Alhamad

引用次数: 1

Abstract

The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft survival. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a new biomarker in the field of kidney transplantation. In this review, we used data from various studies to examine the role of dd-cfDNA in comparison to creatinine and donor-specific antibodies in the early detection of transplant rejection. We also reviewed the use of dd-cfDNA in other organ transplants as well as the challenges and potential future direction for dd-cfDNA as a diagnostic tool.

查看原文本刊更多论文

供体来源的无细胞DNA作为肾移植中的生物标志物。

早期发现同种异体移植物的急性排斥反应是重要的，因为它为及时的治疗干预提供了机会，以保持移植物功能并实现更长的移植物存活时间。供体来源的无细胞DNA（dd-cfDNA）已成为肾移植领域的一种新的生物标志物。在这篇综述中，我们使用了来自各种研究的数据来检查dd-cfDNA与肌酸酐和供体特异性抗体在早期检测移植排斥反应中的作用。我们还回顾了dd-cfDNA在其他器官移植中的应用，以及dd-cfdDNA作为诊断工具的挑战和潜在的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.